Mylan loses Lipidil appeal, despite court finding proof of intention not needed for Swiss-style claims

Appeals 2020-07-03 5:27 pm By Miklos Bolza | Sydney

Please login to bookmark

Mylan Health has lost its challenge to a ruling that invalidated three patents related to its blockbuster cholesterol drug Lipidil, despite the appeals court finding the primary judge had erred by ruling that proof of intention was required for Swiss-style claims.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?

For information on rights and reprints, contact subscriptions@lawyerly.com.au